{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:03:59Z","timestamp":1794891839466,"version":"4.9.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sparks Therapeutics"},{"DOI":"10.13039\/100013394","name":"REGENXBIO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noah's Hope \/ Hope4Bridget"},{"DOI":"10.13039\/100010446","name":"Batten Disease Family Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010446","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005468","name":"Batten Disease Support and Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-based, expert-agreed recommendations on the risks\/benefits of disease-modifying treatments and the medical interventions used to manage this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individuals were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A systematic literature review of published evidence using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance was independently and simultaneously conducted to develop key statements based upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi consensus determination process using the virtual meeting (Within3) online platform which requested experts to agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation (AGREEII) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one international experts from 7 different specialities, including a patient advocate, were identified. Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnostics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Considerations, Social Care Considerations, Pain Management, Epilepsy \/ Seizures, Nutritional Care Interventions, Respiratory Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one exception which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the lowest quality, and 7 represents the highest quality).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This program provides robust evidence- and consensus-driven guidelines that can be used by all healthcare professionals involved in the management of patients with CLN2 disease and other neurodegenerative disorders. This addresses the clinical need to complement other information available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01813-5","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T06:11:12Z","timestamp":1618985472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-4957","authenticated-orcid":false,"given":"Sara E.","family":"Mole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eben","family":"Badoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel F.","family":"Berkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"de Los Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Guelbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joffre E.","family":"Olaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Simonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Von L\u00f6bbecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"1813_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","volume":"16","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag. 2020;16:213\u201322.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"1813_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ddrr.1118","volume":"17","author":"MJ Bennett","year":"2013","unstructured":"Bennett MJ, Rakheja D. The neuronal ceroid-lipofuscinoses. Dev Disabil Res Rev. 2013;17(3):254\u20139.","journal-title":"Dev Disabil Res Rev"},{"issue":"2","key":"1813_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.gene.2016.08.031","volume":"593","author":"DE Sleat","year":"2016","unstructured":"Sleat DE, Gedvilaite E, Zhang Y, Lobel P, Xing J. Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis. Gene. 2016;593(2):284\u201391.","journal-title":"Gene"},{"issue":"3","key":"1813_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","volume":"74","author":"SJ Moore","year":"2008","unstructured":"Moore SJ, Buckley DJ, MacMillan A, Marshall HD, Steele L, Ray PN, et al. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. Clin Genet. 2008;74(3):213\u201322.","journal-title":"Clin Genet"},{"key":"1813_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1172-8-19","volume":"8","author":"FM Santorelli","year":"2013","unstructured":"Santorelli FM, Garavaglia B, Cardona F, Nardocci N, Bernardina BD, Sartori S, et al. Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet J Rare Dis. 2013;8:19.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1813_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1086\/302427","volume":"64","author":"DE Sleat","year":"1999","unstructured":"Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower-Brooks S, Pullarkat RK, et al. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999;64(6):1511\u201323.","journal-title":"Am J Hum Genet"},{"issue":"Suppl 1","key":"1813_CR7","first-page":"682","volume":"13","author":"A Kohlschutter","year":"2016","unstructured":"Kohlschutter A, Schulz A. CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev. 2016;13(Suppl 1):682\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"1813_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","volume":"62","author":"M Haltia","year":"2003","unstructured":"Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 2003;62(1):1\u201313.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"1813_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bbadis.2012.11.014","volume":"1832","author":"GW Anderson","year":"2013","unstructured":"Anderson GW, Goebel HH, Simonati A. Human pathology in NCL. Biochim Biophys Acta. 2013;1832(11):1807\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"1813_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101\u20135.","journal-title":"J Child Neurol"},{"issue":"3","key":"1813_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00018-010-0468-6","volume":"68","author":"AL Getty","year":"2011","unstructured":"Getty AL, Pearce DA. Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell Mol Life Sci. 2011;68(3):453\u201374.","journal-title":"Cell Mol Life Sci"},{"issue":"1\u20132","key":"1813_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","volume":"119","author":"M Fietz","year":"2016","unstructured":"Fietz M, AlSayed M, Burke D, Cohen-Pfeffer J, Cooper JD, Dvorakova L, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119(1\u20132):160\u20137.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"1813_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/clinchem\/46.7.1005","volume":"46","author":"I Sohar","year":"2000","unstructured":"Sohar I, Lin L, Lobel P. Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays. Clin Chem. 2000;46(7):1005\u20138.","journal-title":"Clin Chem"},{"issue":"20","key":"1813_CR14","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los RE, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u2013907.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1813_CR15","doi-asserted-by":"publisher","first-page":"e000791","DOI":"10.1136\/rmdopen-2018-000791","volume":"4","author":"M Mosca","year":"2018","unstructured":"Mosca M, Cutolo M. Clinical practice guidelines: the first year of activity of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). RMD Open. 2018;4(Suppl 1):e000791.","journal-title":"RMD Open"},{"issue":"3","key":"1813_CR16","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.15190\/d.2015.42","volume":"3","author":"O Bucur","year":"2015","unstructured":"Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, et al. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015;3(3):e50.","journal-title":"Discoveries (Craiova)"},{"issue":"2","key":"1813_CR17","first-page":"71","volume":"126","author":"CJDJ Hendriksz","year":"2019","unstructured":"Hendriksz CJDJ, Donohue Y, Mole SE. Methodology to develop guidelines for the management of patients with neuronal ceroid lipofuscinosis type 2 disease. Mol Genet Metab. 2019;126(2):71.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1813_CR18","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123\u201330.","journal-title":"Open Med."},{"key":"1813_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1813_CR20","volume-title":"GeneReviews((R))","author":"SE Mole","year":"1993","unstructured":"Mole SE, Williams RE, et al. Neuronal ceroid-lipofuscinoses\u2014archived chapter, for historical reference only. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle, WA: University of Washington; 1993."},{"key":"1813_CR21","first-page":"1","volume":"17","author":"BC Wallace","year":"2016","unstructured":"Wallace BC, Kuiper J, Sharma A, Zhu MB, Marshall IJ. Extracting PICO sentences from clinical trial reports using supervised distant supervision. J Mach Learn Res. 2016;17:1\u201315.","journal-title":"J Mach Learn Res"},{"key":"1813_CR22","unstructured":"Medicine CfE-B. Oxford centre for evidence-based medicine - Levels of evidence working group 2011. https:\/\/www.cebm.net\/2016\/05\/ocebm-levels-of-evidence\/."},{"issue":"1","key":"1813_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305\u201310.","journal-title":"Plast Reconstr Surg"},{"key":"1813_CR24","unstructured":"3 W. Within3 Healthcare Engagement Solutions. https:\/\/www.within3.com\/."},{"key":"1813_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102\u201312.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1813_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1813_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40271-019-00389-4","volume":"13","author":"D Khodyakov","year":"2020","unstructured":"Khodyakov D, Grant S, Denger B, Kinnett K, Martin A, Peay H, et al. Practical considerations in using online modified-Delphi approaches to engage patients and other stakeholders in clinical practice guideline development. Patient. 2020;13(1):11\u201321.","journal-title":"Patient"},{"key":"1813_CR28","first-page":"i1152","volume":"352","author":"Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS","year":"2016","unstructured":"Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152.","journal-title":"BMJ"},{"issue":"11","key":"1813_CR29","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","volume":"1832","author":"A Schulz","year":"2013","unstructured":"Schulz A, Kohlschutter A, Mink J, Simonati A, Williams R. NCL diseases\u2014clinical perspectives. Biochim Biophys Acta. 2013;1832(11):1801\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1813_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0883073812448459","volume":"28","author":"MS Perez-Poyato","year":"2013","unstructured":"Perez-Poyato MS, Marfa MP, Abizanda IF, Rodriguez-Revenga L, Sanchez VC, Gonzalez MJ, et al. Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013;28(4):470\u20138.","journal-title":"J Child Neurol"},{"issue":"11","key":"1813_CR31","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","volume":"40","author":"E Gardner","year":"2019","unstructured":"Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019;40(11):1924\u201338.","journal-title":"Hum Mutat"},{"issue":"1","key":"1813_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00401-008-0349-3","volume":"116","author":"M Elleder","year":"2008","unstructured":"Elleder M, Dvorakova L, Stolnaja L, Vlaskova H, Hulkova H, Druga R, et al. Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol. 2008;116(1):119\u201324.","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"1813_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jns.2015.05.021","volume":"356","author":"R Di Giacopo","year":"2015","unstructured":"Di Giacopo R, Cianetti L, Caputo V, La Torraca I, Piemonte F, Ciolfi A, et al. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: clinical, molecular and biochemical characterization in three sibs. J Neurol Sci. 2015;356(1\u20132):65\u201371.","journal-title":"J Neurol Sci"},{"issue":"5","key":"1813_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/humu.22292","volume":"34","author":"Y Sun","year":"2013","unstructured":"Sun Y, Almomani R, Breedveld GJ, Santen GW, Aten E, Lefeber DJ, et al. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease). Hum Mutat. 2013;34(5):706\u201313.","journal-title":"Hum Mutat"},{"issue":"8","key":"1813_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"1813_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/jnnp.38.10.985","volume":"38","author":"HH Goebel","year":"1975","unstructured":"Goebel HH, Zeman W, Pilz H. Significance of muscle biopsies in neuronal ceroid-lipofuscinoses. J Neurol Neurosurg Psychiatry. 1975;38(10):985\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1813_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0387-7604(79)80030-3","volume":"1","author":"T Yamano","year":"1979","unstructured":"Yamano T, Shimada M, Okada S, Yutaka T, Yabuuchi H, Nakao Y. Electron microscopic examination of skin and conjunctival biopsy specimens in neuronal storage diseases. Brain Dev. 1979;1(1):16\u201325.","journal-title":"Brain Dev"},{"issue":"5","key":"1813_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00000372-199310000-00008","volume":"15","author":"M Carlesimo","year":"1993","unstructured":"Carlesimo M, Giustini S, Rossodivita A, Cardona F, Calvieri S. Late infantile ceroid-lipofuscinoses. An ultrastructural study. Am J Dermatopathol. 1993;15(5):456\u201360.","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"1813_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0387-7604(79)80043-1","volume":"1","author":"K Ikeda","year":"1979","unstructured":"Ikeda K, Goebel HH. Ultrastructural pathology of lymphocytes in neuronal ceroid-lipofuscinoses. Brain Dev. 1979;1(4):285\u201392.","journal-title":"Brain Dev"},{"issue":"5","key":"1813_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/01913120500406566","volume":"30","author":"GW Anderson","year":"2006","unstructured":"Anderson GW, Smith VV, Brooke I, Malone M, Sebire NJ. Diagnosis of neuronal ceroid lipofuscinosis (Batten disease) by electron microscopy in peripheral blood specimens. Ultrastruct Pathol. 2006;30(5):373\u20138.","journal-title":"Ultrastruct Pathol"},{"issue":"9","key":"1813_CR41","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archneur.1976.00500090036007","volume":"33","author":"WR Markesbery","year":"1976","unstructured":"Markesbery WR, Shield LK, Egel RT, Jameson HD. Late-infantile neuronal ceroid-lipofuscinosis. An ultrastructural study of lymphocyte inclusions. Arch Neurol. 1976;33(9):630\u20135.","journal-title":"Arch Neurol."},{"issue":"7","key":"1813_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S0344-0338(11)80757-0","volume":"190","author":"HH Goebel","year":"1994","unstructured":"Goebel HH. Prenatal ultrastructural diagnosis in the neuronal ceroid-lipofuscinoses. Pathol Res Pract. 1994;190(7):728\u201333.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"1813_CR43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ajmg.1320220413","volume":"22","author":"PM MacLeod","year":"1985","unstructured":"MacLeod PM, Dolman CL, Nickel RE, Chang E, Nag S, Zonana J, et al. Prenatal diagnosis of neuronal ceroid-lipofuscinoses. Am J Med Genet. 1985;22(4):781\u20139.","journal-title":"Am J Med Genet"},{"issue":"2","key":"1813_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/1531-8249(200002)47:2<254::AID-ANA19>3.0.CO;2-7","volume":"47","author":"E Berry-Kravis","year":"2000","unstructured":"Berry-Kravis E, Sleat DE, Sohar I, Meyer P, Donnelly R, Lobel P. Prenatal testing for late infantile neuronal ceroid lipofuscinosis. Ann Neurol. 2000;47(2):254\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"1813_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/1097-0223(200102)21:2<99::AID-PD988>3.0.CO;2-F","volume":"21","author":"WJ Kleijer","year":"2001","unstructured":"Kleijer WJ, van Diggelen OP, Keulemans JL, Losekoot M, Garritsen VH, Stroink H, et al. First-trimester diagnosis of late-infantile neuronal ceroid lipofuscinosis (LINCL) by tripeptidyl peptidase I assay and CLN2 mutation analysis. Prenat Diagn. 2001;21(2):99\u2013101.","journal-title":"Prenat Diagn"},{"issue":"1","key":"1813_CR46","first-page":"20","volume":"37","author":"N Zhong","year":"2005","unstructured":"Zhong N, Ju W, Moroziewicz D, Wronska A, Li M, Wisniewski K, et al. Prenatal diagnostic testing for infantile and late-infantile neuronal ceroid lipofusinoses (NCL) using allele specific primer extension (ASPE). Beijing Da Xue Xue Bao Yi Xue Ban. 2005;37(1):20\u20135.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"8","key":"1813_CR47","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1212\/WNL.54.8.1676","volume":"54","author":"Y Kurachi","year":"2000","unstructured":"Kurachi Y, Oka A, Mizuguchi M, Ohkoshi Y, Sasaki M, Itoh M, et al. Rapid immunologic diagnosis of classic late infantile neuronal ceroid lipofuscinosis. Neurology. 2000;54(8):1676\u201380.","journal-title":"Neurology"},{"issue":"2","key":"1813_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1471-4159.1999.0730700.x","volume":"73","author":"I Sohar","year":"1999","unstructured":"Sohar I, Sleat DE, Jadot M, Lobel P. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J Neurochem. 1999;73(2):700\u201311.","journal-title":"J Neurochem"},{"issue":"Suppl A","key":"1813_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/ejpn.2000.0454","volume":"5","author":"P Santavuori","year":"2001","unstructured":"Santavuori P, Vanhanen SL, Autti T. Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders. Eur J Paediatr Neurol. 2001;5(Suppl A):157\u201361.","journal-title":"Eur J Paediatr Neurol."},{"issue":"13","key":"1813_CR50","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1177\/0883073816658659","volume":"31","author":"DV Albert","year":"2016","unstructured":"Albert DV, Yin H, De Los Reyes EC, Vidaurre J. Unique Characteristics of the photoparoxysmal response in patients with neuronal ceroid lipofuscinosis type 2: can EEG be a biomarker? J Child Neurol. 2016;31(13):1475\u201382.","journal-title":"J Child Neurol"},{"issue":"1","key":"1813_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jnnp.36.1.68","volume":"36","author":"G Pampiglione","year":"1973","unstructured":"Pampiglione G, Harden A. Neurophysiological identification of a late infantile form of \u201cneuronal lipidosis.\u201d J Neurol Neurosurg Psychiatry. 1973;36(1):68\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1813_CR52","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/epi.13820","volume":"58","author":"N Specchio","year":"2017","unstructured":"Specchio N, Bellusci M, Pietrafusa N, Trivisano M, de Palma L, Vigevano F. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia. 2017;58(8):1380\u20138.","journal-title":"Epilepsia"},{"issue":"8","key":"1813_CR53","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","volume":"8","author":"A Orlin","year":"2013","unstructured":"Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky\u2013Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS ONE. 2013;8(8):e73128.","journal-title":"PLoS ONE"},{"issue":"2","key":"1813_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajmg.1320570225","volume":"57","author":"P Heim","year":"1995","unstructured":"Heim P, Kohlschutter A. Avoid diagnostic delay of late infantile and juvenile neuronal ceroid-lipofuscinosis (LINCL, JNCL): a word to pediatricians, neurologists, and ophthalmologists. Am J Med Genet. 1995;57(2):238.","journal-title":"Am J Med Genet"},{"issue":"3","key":"1813_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/10906570050501452","volume":"4","author":"NA Zhong","year":"2000","unstructured":"Zhong NA, Wisniewski KE, Ju W, Moroziewicz DN, Jurkiewicz A, McLendon L, et al. Molecular diagnosis of and carrier screening for the neuronal ceroid lipofuscinoses. Genet Test. 2000;4(3):243\u20138.","journal-title":"Genet Test"},{"key":"1813_CR56","unstructured":"International children\u2019s palliative care network. http:\/\/www.icpcn.org\/standards-guidelines\/."},{"issue":"4","key":"1813_CR57","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajmg.1320420421","volume":"42","author":"RM Boustany","year":"1992","unstructured":"Boustany RM. Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types. Am J Med Genet. 1992;42(4):533\u20135.","journal-title":"Am J Med Genet"},{"issue":"6","key":"1813_CR58","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","volume":"69","author":"S Worgall","year":"2007","unstructured":"Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007;69(6):521\u201335.","journal-title":"Neurology"},{"issue":"6","key":"1813_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1212\/01.wnl.0000269663.23404.c5","volume":"69","author":"D Ramirez-Montealegre","year":"2007","unstructured":"Ramirez-Montealegre D, Pearce DA. Imaging of late infantile neuronal ceroid lipofuscinosis: a clinical rating scale. Neurology. 2007;69(6):503\u20134.","journal-title":"Neurology"},{"issue":"4","key":"1813_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347\u201354.","journal-title":"Am J Med Genet"},{"issue":"4","key":"1813_CR61","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3174\/ajnr.A3297","volume":"34","author":"JP Dyke","year":"2013","unstructured":"Dyke JP, Sondhi D, Voss HU, Shungu DC, Mao X, Yohay K, et al. Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am J Neuroradiol. 2013;34(4):884\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1813_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2019.07.003","volume":"100","author":"HT Chugani","year":"2019","unstructured":"Chugani HT. Positron emission tomography in pediatric neurodegenerative disorders. Pediatr Neurol. 2019;100:12\u201325.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1813_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5935\/0004-2749.20170053","volume":"80","author":"E Quagliato","year":"2017","unstructured":"Quagliato E, Rocha DM, Sacai PY, Watanabe SS, Salomao SR, Berezovsky A. Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. Arq Bras Oftalmol. 2017;80(4):215\u20139.","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"1813_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","volume":"33","author":"A Kohlschutter","year":"2019","unstructured":"Kohlschutter A, Schulz A, Bartsch U, Storch S. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs. 2019;33(4):315\u201325.","journal-title":"CNS Drugs"},{"issue":"11","key":"1813_CR65","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Cerliponase alfa: first global approval. Drugs. 2017;77(11):1247\u20139.","journal-title":"Drugs"},{"key":"1813_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","volume":"197","author":"A Cherukuri","year":"2018","unstructured":"Cherukuri A, Cahan H, de Hart G, Van Tuyl A, Slasor P, Bray L, et al. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a Phase 1\/2 study. Clin Immunol. 2018;197:68\u201376.","journal-title":"Clin Immunol"},{"issue":"2","key":"1813_CR67","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1213\/ane.0b013e3181aa6e95","volume":"109","author":"N Miao","year":"2009","unstructured":"Miao N, Levin SW, Baker EH, Caruso RC, Zhang Z, Gropman A, et al. Children with infantile neuronal ceroid lipofuscinosis have an increased risk of hypothermia and bradycardia during anesthesia. Anesth Analg. 2009;109(2):372\u20138.","journal-title":"Anesth Analg"},{"issue":"1","key":"1813_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03020423","volume":"49","author":"Y Yamada","year":"2002","unstructured":"Yamada Y, Doi K, Sakura S, Saito Y. Anesthetic management for a patient with Jansky-Bielschowsky disease. Can J Anaesth. 2002;49(1):81\u20133.","journal-title":"Can J Anaesth."},{"issue":"7","key":"1813_CR69","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1469-8749.2011.04170.x","volume":"54","author":"S Fukumura","year":"2012","unstructured":"Fukumura S, Saito Y, Saito T, Komaki H, Nakagawa E, Sugai K, et al. Progressive conduction defects and cardiac death in late infantile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2012;54(7):663\u20136.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"1813_CR70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161\u201378.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1813_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Kleine Holthaus SM, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107\u201316.","journal-title":"Lancet Neurol"},{"key":"1813_CR72","unstructured":"Nursing Rco. Breaking bad news: supporting parents when they are told of their child\u2019s diagnosis 2013 [updated 7 May 2020]. https:\/\/www.rcn.org.uk\/professional-development\/publications\/pub-004471."},{"issue":"9","key":"1813_CR73","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1651-2227.2012.02680.x","volume":"101","author":"C Malcolm","year":"2012","unstructured":"Malcolm C, Hain R, Gibson F, Adams S, Anderson G, Forbat L. Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families. Acta Paediatr. 2012;101(9):985\u201392.","journal-title":"Acta Paediatr"},{"issue":"2","key":"1813_CR74","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1155\/2009\/642352","volume":"14","author":"LM Breau","year":"2009","unstructured":"Breau LM, Burkitt C. Assessing pain in children with intellectual disabilities. Pain Res Manag. 2009;14(2):116\u201320.","journal-title":"Pain Res Manag"},{"issue":"11","key":"1813_CR75","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/AJP.0000000000000192","volume":"31","author":"CC Barney","year":"2015","unstructured":"Barney CC, Hoch J, Byiers B, Dimian A, Symons FJ. A case-controlled investigation of pain experience and sensory function in neuronal ceroid lipofuscinosis. Clin J Pain. 2015;31(11):998\u20131003.","journal-title":"Clin J Pain"},{"issue":"11","key":"1813_CR76","first-page":"1244","volume":"62","author":"M Kacinski","year":"2005","unstructured":"Kacinski M, Kroczka S, Zajac A, Jaworek M. Epilepsy with polymorphic seizures in hospitalized children. Przegl Lek. 2005;62(11):1244\u20138.","journal-title":"Przegl Lek"},{"issue":"3","key":"1813_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0036-1579784","volume":"47","author":"J Johannsen","year":"2016","unstructured":"Johannsen J, Nickel M, Schulz A, Denecke J. Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease. Neuropediatrics. 2016;47(3):194\u20136.","journal-title":"Neuropediatrics"},{"issue":"1\u20132","key":"1813_CR78","first-page":"40","volume":"25","author":"R Lorenz","year":"2004","unstructured":"Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett. 2004;25(1\u20132):40\u20134.","journal-title":"Neuro Endocrinol Lett"},{"key":"1813_CR79","first-page":"S1","volume":"50","author":"ESA Wibbeler","year":"2019","unstructured":"Wibbeler ESA, Nickel M, Schwering C. Experiences with cannabidiol in patients with NCL disease. Neuropediatrics. 2019;50:S1\u201355.","journal-title":"Neuropediatrics"},{"issue":"3","key":"1813_CR80","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.eplepsyres.2012.01.015","volume":"100","author":"S Nangia","year":"2012","unstructured":"Nangia S, Caraballo RH, Kang HC, Nordli DR, Scheffer IE. Is the ketogenic diet effective in specific epilepsy syndromes? Epilepsy Res. 2012;100(3):252\u20137.","journal-title":"Epilepsy Res"},{"key":"1813_CR81","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2016.02.009","volume":"59","author":"LM Lehwald","year":"2016","unstructured":"Lehwald LM, Pappa R, Steward S, de Los RE. Neuronal ceroid lipofuscinosis and associated sleep abnormalities. Pediatr Neurol. 2016;59:30\u20135.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"1813_CR82","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/archdischild-2017-314181","volume":"103","author":"IS Abdelgadir","year":"2018","unstructured":"Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103(12):1155\u201362.","journal-title":"Arch Dis Child"},{"issue":"4","key":"1813_CR83","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1006\/mgme.1999.2815","volume":"66","author":"T Hatonen","year":"1999","unstructured":"Hatonen T, Kirveskari E, Heiskala H, Sainio K, Laakso ML, Santavuori P. Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy. Mol Genet Metab. 1999;66(4):401\u20136.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1813_CR84","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"1","key":"1813_CR85","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1813_CR86","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jep.12428","volume":"21","author":"Y Osara","year":"2015","unstructured":"Osara Y, Coakley K, Aisthorpe A, Stembridge A, Quirk M, Splett PL, et al. The role of evidence analysts in creating nutrition management guidelines for inherited metabolic disorders. J Eval Clin Pract. 2015;21(6):1235\u201343.","journal-title":"J Eval Clin Pract"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01813-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01813-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T06:24:47Z","timestamp":1618986287000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01813-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01813-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-96773\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Sara Mole: Declares personal fees from Care Beyond Diagnosis for professional advice; Grants from BioMarin outside the submitted work. Dr Angela Schulz: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares a grant and personal fees received from BioMarin for honoraria and advisory board attendance. Prof. E. Badoe: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr S. Berkovic: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. Emily de Los Reyes: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares a grant and personal fees received from BioMarin for consultation services. Dr. Simon Dulz: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr P. Gissen: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares a grant and personal fees received from BioMarin, during the conduct of the study. Dr. N. Guelbert: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. C. Lourenco: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. Heather L. Mason: Declares personal fees from Care Beyond Diagnosis for professional medical writing services. Ms N. Murphy: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. J. W. Mink: Declares personal fees from Care Beyond Diagnosis for professional advice; Reports personal fees from Neurogene, Inc., personal fees from Amicus, Inc., grants from Beyond Batten Disease Foundation, grants from Abeona Inc., personal fees from Abide Therapeutics, personal fees from Censa Inc., personal fees from Cipla, Inc., personal fees from TEVA Inc., outside the submitted work. Dr M. Nickel: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. J. Olaya: Declares personal fees from Care Beyond Diagnosis for professional advice. Dr. M Scarpa: Declares personal fees from Care Beyond Diagnosis for professional advice. Prof. I. Scheffer: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares receipt of grants from NHMRC, grants from NIH, during the conduct of the study; personal fees from GlaxoSmithKline, personal fees from Eisai, personal fees from Nutricia, personal fees from GW Pharmaceutical, personal fees from Xeonon, personal fees from BioCodex, personal fees from BioMarin, personal fees from UCB, outside the submitted work; In addition, Dr. Scheffer has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies;\u00a0was a consultant to Bionomics and Athena diagnostics previously, and holds a patent Molecular diagnostic\/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT\/AU2012\/001321\u00d0u8226\u2022 TECH ID:2012-009 with royalties paid. Dr. A. Simonati: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares personal fees received from BioMarin, Neurogene Inc, UCB SA, for honoraria and advisory board attendance. Dr. N. Specchio: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares receipt of a grant from BioMarin, outside of the submitted work. Dr. I. von L\u00f6bbecke: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares receipt of personal fees from and BioMarin. Dr. R. Wang: Declares personal fees from Care Beyond Diagnosis for professional advice; Declares receipt of a grant, research funding, honoraria for advisory board attendance, and equity ownership from BioMarin and RegenxBio Inc. Dr Ruth E. Williams: Declares personal fees from Care Beyond Diagnosis for professional advice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}